Funding extension brings in $8M for antibody drug developer

04/1/2013 | MedCityNews.com

Theraclone Sciences secured an additional $8 million, bringing the total raised in its Series B funding round to $50 million. The Seattle biotech company is developing two antibodies for severe flu and cytomegalovirus infection.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN